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Abstract
Background: The polycomb group (PcG) protein BMI1 is an important regulator of development. Additionally, 
aberrant expression of BMI1 has been linked to cancer stem cell phenotype and oncogenesis. In particular, its 
overexpression has been found in several human malignancies including breast cancer. Despite its established role in 
stem cell maintenance, cancer and development, at present not much is known about the functional domains of BMI1 
oncoprotein. In the present study, we carried out a deletion analysis of BMI1 to identify its negative regulatory domain.
Results: We report that deletion of the C-terminal domain of BMI1, which is rich in proline-serine (PS) residues and 
previously described as PEST-like domain, increased the stability of BMI1, and promoted its pro-oncogenic activities in 
human mammary epithelial cells (HMECs). Specifically, overexpression of a PS region deleted mutant of BMI1 increased 
proliferation of HMECs and promoted an epithelial-mesenchymal transition (EMT) phenotype in the HMECs. 
Furthermore, when compared to the wild type BMI1, exogenous expression of the mutant BMI1 led to a significant 
downregulation of p16INK4a and an efficient bypass of cellular senescence in human diploid fibroblasts.
Conclusions: In summary, our data suggest that the PS domain of BMI1 is involved in its stability and that it negatively 
regulates function of BMI1 oncoprotein. Our results also suggest that the PS domain of BMI1 could be targeted for the 
treatment of proliferative disorders such as cancer and aging.
Background
Polycomb Group (PcG) proteins originally discovered in
Drosophila are evolutionarily conserved epigenetic regu-
lators of development [1-3]. These proteins regulate pro-
liferation and differentiation of cells via epigenetic
silencing of important growth regulatory genes [3,4]. The
first mammalian PcG gene BMI1 (B lymphoma Mo-MLV
insertion region 1) was identified as a c-myc cooperating
oncogene using an Eμ-myc transgenic mouse model [5,6].
There is increasing evidence that the deregulated expres-
sion of BMI1 contributes to cancer development. It is
overexpressed in a number of cancers, such as mantle cell
lymphoma [7], B-cell non-Hodgkin's lymphoma [8],
myeloid leukemia [9], non-small cell lung cancer [10],
colorectal cancer [11], breast and prostate cancers
[12,13], and head and neck cancers [14,15]. In addition to
its role in cancer, BMI1 is also known to be required for
self-renewal of neural, hematopoietic, intestinal and
mammary stem cells [16-21]. Consistent with its role in
stem cell self-renewal, BMI1 expression is thought to pro-
mote stem-ness in tumor cells [12,22], and BMI1 is con-
sidered an important marker of breast cancer stem cells
[23]. Recent mouse xenograft studies using BMI1 and Ras
co-overexpressing human mammary epithelial cells
(HMECs) also support oncogenic roles for BMI1 in breast
cancer development and metastasis of breast cancer cells
[24,25].
PcG proteins assemble into polycomb repressive com-
plexes (PRCs), which possess histone posttranslational
modification (PTM) activities and act in a sequential
fashion to mediate gene silencing [3]. Biochemically,
BMI1 is a core component of PRC1, which ubiquitinates
histone 2A at lysine 119 residue [26], and acts down-
stream of PRC2, which trimethylates lysine 27 residue of
histone 3 [27,28]. Although BMI1 is a prominent compo-
nent of PRC1, its exact role in PRC1 is unclear. BMI1 by
itself does not appear to have an E3 ubiquitin ligase activ-
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ity [29], instead, the E3 ubiquitin ligase activity of PRC1
strictly depends on Ring1B (RING2) protein. However, it
has been shown that Ring1B-mediated E3 ubiquitin ligase
activity of PRC1 complex is enhanced by BMI1 [29-31].
Structurally, human BMI1 is comprised of 326 amino
acids [32]. The primary structure of BMI1 in mice
revealed the presence of a RING finger (RF) domain at
the N-terminus, a potential HTH (helix turn helix)
domain in the middle and a PEST (proline (P), glutamic
acid (E), serine (S) and threonine (T) rich) -like domain at
the C-terminus [5,6]. These domains of BMI1 are highly
conserved across mammalian species including human.
The BMI1 also contains two putative nuclear localization
signals (NLS), NLS1 (KRRR, amino acid residues 92-95)
and NLS2 (KRMK, amino acid residues 232-235). Of
these two, only NLS2 appears to be functional in target-
ing BMI1 to the nucleus in mouse and human cells
[33,34]. We have previously carried out functional analy-
sis of BMI1 and shown that the RING finger and HTH
domains of BMI1 are required for downregulation of
p16INK4a tumor suppressor and bypass of senescence in
human diploid fibroblasts (HDFs) [35]. We also showed
that both of these domains are required for immortaliza-
tion of normal HMECs [34].
PEST-like domains rich in proline (P), glutamic acid
(E), serine (S) and threonine (T) residues have been
described in the literature [36]. Although the actual con-
tribution of such domains to protein turn-over is not
clear and such sequences may not mediate proteolysis per
se, the PEST-like domains are present in many proteins
that undergo rapid turn-over such as cyclins, NF-κβ, c-
Myc, c-Fos, ODC, ABCA1 etc [36-44]. Since a PEST-like
domain, which is rich in proline (P) and serine (S) resi-
dues is present in BMI1 [5,6], and at present very little is
known about its functional role, we carried out a struc-
tural-functional analysis of BMI1 to define the role of this
domain in BMI1. As the PEST-like domain in BMI1 is not
rich in E- and T- residues, here in, we refer this domain as
the PS domain. Our data indicate that the PS domain of
BMI1 may indeed regulate its proteolysis and that it may
function as a negative regulatory domain of BMI1.
Results
Deletion of the PS domain results in increased half life of 
BMI1
W e have previously reported that the RING finger and
HTH domains of BMI1 are required for its pro-prolifera-
tive activities and to enable bypass of senescence in HDFs
and HMECs [34,35]. To further understand the role of the
various domains of BMI1, we generated a PS deletion
mutant which we termed as ΔPS mutant (Fig. 1A), and
used it as a tool to study the biochemical and posttransla-
tional regulation of BMI1. MCF10A cells stably express-
ing wild type (WT), and ΔRF, ΔHT and ΔPS mutants of
BMI1 were selected in puromycin as described in the
Materials and Methods section. The drug-selected cells
were further passaged in culture and the half lives of wild
type and mutant BMI1 proteins were determined using
cyclohexamide (CHX) treatment at different time points.
Our results indicated that the wild type BMI1 has a half
life of ~25 minutes and that the ΔRF, and ΔHT mutants
degraded faster than the wild type BMI1 with a half life of
15-20 minutes (Fig. 1B). On the other hand, ΔPS mutant
of BMI1 was relatively very stable and did not undergo
any significant proteolysis up to 60 minutes (Fig. 1B).
To determine the half life of the ΔPS mutant of BMI1,
MCF10A-BMI1WT and MCF10A-BMI1ΔPS cells were
further treated with CHX for longer periods (0-240 min)
and the half lives of the wild type BMI1 and ΔPS mutant
were determined as described above. Our results indi-
cated that the half life of ΔPS mutant of BMI1 is about
120 min (Fig. 2A). We also determined the rate of prote-
olysis of endogenous BMI1 in MCF10A-BMI1ΔPS cells.
Our analysis of the half life of BMI1 proteins indicated
that, similar to the overexpressed wild type BMI1, the
endogenous BMI1 also has a half life of 25-30 min in
MCF10A cells (Fig. 2A lower panel).
During our analysis of BMI1 half life, we noticed that
the wild type but not the ΔPS mutant of BMI1 is detected
as multiple bands of different mobility, and that the inten-
sity of the slow mobility bands increases with CHX treat-
ment. To determine whether the slow mobility bands
represent phosphorylated forms of BMI1, we treated total
cell extract of MCF10A-BMI1 cells with calf intestinal
alkaline phosphatase (CIP) and performed an immunob-
lot analysis (IB) of BMI1. Our results indicated that the
slower mobility bands of BMI1 likely do represent phos-
phorylated forms of BMI1, which disappear upon CIP
treatment (Additional file 1, Fig. S1A).
To further confirm the relatively stable nature of the
ΔPS mutant of BMI1, we treated MCF10A-BMI1WT and
MCF10A-BMI1ΔPS cells with a proteosome inhibitor
MG132 at different time points. We reasoned that if the
ΔPS mutant is more stable than the wild type BMI1 and is
not degraded as fast as the wild type, it will not accumu-
late upon MG132 treatment, which is a commonly used
to inhibit 26S proteosome. Indeed, our results indicated
that the wild type BMI1 is accumulated within 30 min
upon MG132-treatment, while the ΔPS mutant of BMI1
had not accumulated after 30 min of treatment (Fig. 2B).
Our data also indicated that longer treatment of MG132
results in accumulation of ΔPS mutant of BMI1; however,
compared to the wild type, the relative accumulation of
ΔPS mutant of BMI1 was much less pronounced at all the
time points we analyzed (Fig. 2B).
To determine whether BMI1 is non-specifically
degraded by proteases, we treated cells with two com-
monly used protease inhibitors; phenylmethylsulfonylYadav et al. Molecular Cancer 2010, 9:158
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fluoride (PMSF) and aprotinin. We also used lactacystin,
another specific inhibitor of 26S-proteosome. After treat-
ment of the cells with PMSF, aprotinin and lactacystin,
BMI1 was detected by IB analysis. Our results indicated
that BMI1 is accumulated only in lactacystin-treated cells
(Additional file 1, Fig. S1B). Thus, BMI1 is specifically
degraded by a 26S proteosome-mediated protein degra-
dation pathway. Finally, we also determined the half life of
wild type BMI1 and ΔPS mutants in HDFs. The results
indicate that similar to what we saw in MCF10A cells, the
wild type BMI1 has a half life of ~25 min in MRC5 and
IMR90 strains of HDFs, while the ΔPS mutant of BMI1 is
very stable in these cells (Additional file 1, Fig. S2 and Fig.
S3). Collectively, our data suggest that deletion of the PS
Figure 1 Deletion of the PS domain of BMI1 results in increased half life of BMI1. (A). Schematic representation of wild type BMI1 and its deletion 
mutants. The domain structure of the wild type BMI1, and the ΔHT and ΔRF mutants has been described previously [34,35]. The ΔPS mutant of BMI1 
encodes a protein, which lacks amino acids 236- 326. Its cDNA was generated by PCR and cloned in the pBabe- puro retroviral vector. (B). The half life 
of wild type and mutant BMI1 in MCF10A cells expressing the respective protein was determined by blocking synthesis of new proteins using 100 μg/
ml CHX for different time points (0-60 min) and the rate of BMI1 degradation was determined by western blot analysis of remaining BMI1 protein after 
each time point and normalizing it to ß-actin using densitometry measurements as described in the Materials and Methods section. In case of the wild 
type, and the ΔRF and the ΔHT mutants, only the lower most band of BMI1, which showed a time-dependent decrease was quantified to determine 
the half life. The densitometric analysis was performed using Image J software (NIH, Bethesda, MD), and the graph was generated by plotting % resid-
ual protein vs time of CHX treatment.Yadav et al. Molecular Cancer 2010, 9:158
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domain of BMI1 renders it much more stable compared
to the overexpressed or endogenous wild type BMI1.
Deletion of the PS domain of BMI1 promotes proliferation 
of cells
To determine the possible consequences of deleting the
PS region of BMI1 on PRC1 activity, we examined the
levels of H2A K119Ub in MCF10A-B0 control, MCF10A-
BMI1WT and MCF10A-BMI1ΔPS cells. Our results indi-
cated that the wild type BMI1 increased the levels of H2A
K119Ub and that deletion of the PS region resulted in
further increase in H2A K119Ub levels (Fig. 3A). These
data suggest that the ΔPS mutant of BMI1 may be physio-
logically more active. Previously, we reported that the
overexpression of BMI1 in normal and immortal cells
results in increased proliferation [24,25,34,35]. To deter-
Figure 2 The ΔPS mutant of BMI1 is more stable than the wild type BMI1. (A).The half life of the ΔPS mutant of BMI1 and the wild type BMI1 was 
determined using CHX treatment (0-240 min) of MCF10A-BMI1WT and MCF10A-BMI1ΔPS cells as described above. (B). MCF10A-BMI1WT and MCF10A-
BMI1ΔPS cells were treated with MG132 for different times points (as indicated) to determine its effect on the wild type and the ΔPS mutant of BMI1. 
Cells were harvested after each time point and analyzed for accumulation of the wild type or mutant BMI1 protein by western blot analysis. The ac-
cumulated proteins were quantified by densitometric analysis of signal present in respective lanes and by normalizing it to the individual α-tubulin 
signal. The densitometric analysis was done as described in Fig. 1B.Yadav et al. Molecular Cancer 2010, 9:158
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Figure 3 Deletion of the PS domain of BMI1 augments its pro-proliferative activity and promotes EMT in MCF10A cells. (A). Wild type BMI1 
and ΔPS mutant of BMI1 upregulates H2A K119Ub activity of PRC1. The relative expression of H2A K119Ub in MCF10A control, MCF10A-BMI1WT and 
MCF10A-BMI1ΔPS cells was determined by western blot analysis and densitometry as described in the Materials and Methods section and Fig. 1B. (B). 
MCF10A-derived cells expressing wild type and mutant BMI1 were plated in P100 plastic dishes (5 × 105/plate). Cells were harvested at the indicated 
day (days 1-5) and counted using a hemocytometer. Proliferation curves were generated by plotting the number of cells against number of days. (C). 
Increase in AKT activity (phospho-AKT and phospho-GSK3β), and the expression of AKT/GSK3β targets cyclin D1 and CDK4 was determined by western 
blot analysis using antibody specific to each protein as described in the Materials and Methods section. β-actin was used as a loading control. The 
relative expression of phospho-AKT (normalized to total AKT), Phospho-GSK3β (normalized to total GSK3β), CDK4 (normalized to β-actin) and cyclin 
D1 (normalized to β-actin) was quantified by densitometry as described in Fig. 1B. (D). MCF10A-derived cells expressing wild type BMI1 or the ΔPS 
mutant were analyzed for the expression of E-cadherin, fibronectin and vimentin using western blot analysis. α-tubulin was used as a loading control. 
(E). The expression of E-cadherin, vimentin and fibronectin in control, and wild type BMI1- and ΔPS mutant-overexpressing cells was determined by 
immunostaining as described in the Materials and Methods section. After immunostaining, cells were photographed (10X) using a Nikon Eclipse 80i 
confocal microscope.Yadav et al. Molecular Cancer 2010, 9:158
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mine whether deletion of the PS region further promotes
proliferation, we examined the rate of proliferation of
MCF10A-B0 control, MCF10A-BMI1WT and MCF10A-
BMI1ΔPS cells. Our data indeed indicated that MCF10A
cells expressing the ΔPS mutant proliferated at a higher
rate than the MCF10A-B0 control and MCF10A-
BMI1WT cells (Fig. 3B). We also previously reported that
BMI1 upregulates AKT in HMECs [45]. Hence, we fur-
ther examined expression of AKT, GSK3β, cyclin D1 and
CDK4 in cells overexpressing the ΔPS mutant of BMI1
and compared it with cells overexpressing the wild type
BMI1. The results of western blot analysis suggested that
while overexpression of the wild type BMI1 results in
modest upregulation of AKT activity (Phospho-AKT)
and cyclin D1, the ΔPS mutant further augmented upreg-
ulation of AKT and cyclin D1 (Fig. 3C). As compared to
overexpression of the wild type (WT) BMI1, no further
upregulation of CDK4 was noticed upon overexpression
of the ΔPS mutant. As a downstream phosphorylation
target of AKT, increased phosphorylation of GSK3β was
also evident in cells overexpressing ΔPS mutant of BMI1
(Fig. 3C). No appreciable changes were noticed in the
expression of total AKT and total GSK3β (Fig. 3C). Thus,
deletion of the PS region of BMI1 further augments the
proliferative activity of BMI1.
Overexpression of the ΔPS mutant of BMI1 results in a 
partially transformed phenotype in HMECs
Because the ΔPS mutant of BMI1 is more stable and more
pro-proliferative, we examined whether its overexpres-
sion can transform MCF10A cells. MCF10A cells overex-
p r e s s i n g  t h e  w i l d  t y p e  B M I 1  o r  t h e  Δ P S  m u t a n t  w e r e
seeded in soft agar and examined for colony formation
over two weeks. The results indicated that neither over-
expression of the wild type BMI1 nor the ΔPS mutant is
sufficient to transform MCF10A cells (not shown). Simi-
larly, overexpression of neither the wild type nor the
mutant BMI1 was sufficient to form foci in 3T3 fibro-
blasts (not shown).
The morphology of MCF10A-BMI1ΔPS cells appeared
to be more fibroblastic than that of the control or the wild
type BMI1 overexpressing cells (Additional file 1, Fig. S4).
The fibroblastic morphological changes in epithelial cells
are suggestive of an EMT phenotype; hence, we analyzed
MCF10A-B0, MCF10A-BMI1WT and MCF10A-
BMI1ΔPS cells for the presence of EMT markers by
immunostaining and western blot analysis (Fig. 3D &3E).
The results indicated that the MCF10A-B0 control and
MCF10A-BMI1 cells expressed E-cadherin, a cell-cell
junction protein characteristic of epithelial cells, while
MCF10A-BMI1ΔPS cells lost the expression of E-cad-
herin (Fig. 3D &3E). In addition, MCF10A- BMI1ΔPS
cells also expressed fibroblastic markers such as vimentin
and fibronectin (Fig. 3D &3E). These data indicate that
the expression of a stable mutant of BMI1 which contains
a deletion of the PS domain can induce an EMT pheno-
type in HMECs. Extensive passaging of the wild type
BMI1 expressing cells, particularly at passages more than
15 after drug selection, also exhibited partial EMT and
loss of E-cadherin expression (not shown). Since exten-
sive passaging of cells in culture can result in the accumu-
lation of additional stochastic lesions, it is possible that
such lesions cooperate with the wild type BMI1 to inhibit
E-cadherin expression and induce a partial EMT pheno-
type.
Next, we performed invasion and wound healing assays
to determine the migratory potential of control and
MCF10A cells overexpressing either the wild type BMI1
or the ΔPS mutant. The results indicated that MCF10A-
BMI1ΔPS cells are highly invasive compared to control
cells, while MCF10A-BMI1 exhibited a modest invasive
potential (Fig. 4A). Similarly, the results of the wound
healing assay suggest that the wild type BMI1 expressing
cells only exhibit a minimal migration, while MCF10A-
BMI1ΔPS cells possess the highest migration potential
and that these cells filled the wound quickly compared to
the MCF10A-B0 control cells (Fig. 4B). Thus, our data
suggest that overexpression of the ΔPS mutant of BMI1
leads to acquisition of migration and invasion properties
indicative of the partial transformation of HMECs.
To further confirm the partial transformation of
HMECs by the ΔPS mutant of BMI1, we analyzed cells for
3-D (3-dimensional) growth in Matrigel. Our data indi-
cated that indeed ΔPS mutants expressing MCF10A cells
are partially transformed (Fig. 5). Specifically, the
MCF10A-B0 control cells formed normal round acini,
while the wild type BMI1 expressing MCF10A cells
formed slightly irregular acini, and the ΔPS mutant
e x p r e s s i n g  M C F 1 0 A  c e l l s  f o r m e d  a  h i g h l y  b r a n c h e d
structure (Fig. 5A). Next, we performed E-cadherin and
α6 integrin immunostaining together with Topro-3
nuclear staining of the acini. The results showed that
MCF10A-B0 cells form normal acini with a proper
lumen; MCF10-BMI1 cells form irregular acini filled with
cells, while there is no lumen-like structure present at all
in the ΔPS mutant expressing MCF10A cells (Fig. 5B).
Furthermore, the MCF10A-BMI1ΔPS cells were devoid
of E-cadherin and α6 integrin confirming induction of
EMT and a partially transformed phenotype in these cells
(Fig. 5).
Overexpression of the ΔPS mutant of BMI1 results in bypass 
of senescence in HDFs
Since MCF10A cells are immortal and do not undergo
replicative senescence, we used HDFs for examining the
effect of overexpression of the ΔPS mutant on senes-
cence. WI-38 cells stably expressing the wild type BMI1
or the PS mutant of BMI1 were generated as described inYadav et al. Molecular Cancer 2010, 9:158
http://www.molecular-cancer.com/content/9/1/158
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the Materials and Methods section. After selection and
culturing for an additional passage, WI-38-derived cells
were analyzed for proliferation and bypass of senescence.
Results of proliferation assays carried over 4 days indi-
cated that WI-38 cells expressing ΔPS mutant prolifer-
a t e d  a t  a  f a s t e r  r a t e  c o m p a r e d  t o  t h e  w i l d  t y p e  B M I 1
expressing cells, which proliferated better than WI-38-B0
control cells (Fig. 6A). We also performed long-term pro-
liferation assays of mid passage WI-38 cells expressing
the wild type BMI1 or the ΔPS mutant. The cells were
continually passaged in culture and the cumulative cell
numbers at each passage were determined to derive a
long-term growth/proliferation curve. The results indi-
cated that the WI-38 cells expressing ΔPS mutant prolif-
erated for more than 50 days before undergoing
senescence, while the control B0 and wild type BMI1-
expressing cells underwent senescence within 15 days
and 25 days of growth after selection respectively (Fig.
6B).
Since BMI1 is known to downregulate p16INK4a in
HDFs, we analyzed WI-38-B0, WI-38-BMI1WT and WI-
38-BMI1PS cells for the expression of p16INK4a. Our
data indicated that, as expected, overexpression of the
w i l d  t y p e  B M I 1  l e d  t o  d o w n r e g u l a t i o n  o f  p 1 6 I N K 4 a .
Importantly, WI-38-BMI1ΔPS cells exhibited even fur-
ther downregulation of p16INK4a (Fig. 6C). Significant
downregulation of p16INK4a by the ΔPS mutant was also
noticed in hTERT-immortalized WI-38 cells (Additional
file 1, Fig. S5). Because p16INK4a regulates senescence
and BMI1 downregulates p16INK4a, cells expressing the
wild type BMI1 or the ΔPS mutant, and control WI-38-
B0 cells were analyzed at the same passage number after
puromycin selection for the induction of spontaneous
senescence using SA-β-gal marker [46]. Consistent with
our earlier data [35], overexpression of BMI1 resulted in
significantly fewer senescent cells when compared to
control B0 cells (Fig. 6D). Importantly, overexpression of
the ΔPS mutant of BMI1 further decreased the number of
senescent cells indicating more efficient bypass of senes-
cence in HDFs (Fig. 6B, D). Thus our data indicate that
the ΔPS mutant of BMI1 is physiologically more active
and pro-proliferative as compared to the wild type BMI1.
With respect to proliferation and senescence, similar
results were obtained in MRC5, which is another com-
monly used strain of HDFs (Additional file 1, Fig. S6).
Discussion
The mouse Bmi1 gene was cloned by two different groups
in 1991 [5,6], and shortly after that, the human homo-
logue of mouse Bmi1 was cloned [32]. Since then most of
Figure 4 The ΔPS mutant of BMI1 promotes invasion and migration. (A) MCF10A-B0, MCF10A-BMI1WT and MCF10A-BMI1ΔPS were analyzed for 
invasion potential using 24-well BD Biocoat Matrigel Invasion Chambers (BD Biosciences, San Jose, CA) as described in the Materials and Methods sec-
tion. The columns represent mean value of triplicate samples and bars represent SD. (B). The migration potential of MCF10A-derived cells was deter-
mined using a wound healing assay as described in the Materials and Methods section.Yadav et al. Molecular Cancer 2010, 9:158
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the studies on BMI1 have been focused on its role in
oncogenesis and stem cell phenotype, and very few stud-
ies have analyzed the regulation of BMI1. Only recently,
we and others analyzed the transcriptional regulation of
BMI1  [47,48]. At present, virtually nothing is known
about additional transcriptional or posttranslational reg-
ulation of BMI1. Such regulation of BMI1 is likely to be
highly relevant for the role of BMI1 in development and
pathobiology of various diseases, including cancer.
The initial characterization of mouse and human BMI1
predicted the presence of three structural domains in
BMI1; a RING finger domain, an HTH domain and a
potential PEST domain. Except for the RING finger
domain, the functional role of these domains is largely
undefined. The RING finger domain is most recognizable
domain in BMI1. Although such domains are found in E3
ubiquitin ligases, BMI1 by itself lacks E3 ubiquitin ligase
activity. Nonetheless, this domain has been shown to be
functionally important [15,34,35,49].
A  R I N G  f i n g e r  d o m a i n  m u t a n t  o f  B m i 1  ( t h e  m o u s e
homologue of human BMI1) was shown to be ineffective
in collaborating with c-myc to induce B- and T- cell lym-
phomas [49]. Moreover, the deletion of the RING finger
domain of BMI1 may lead to dominant negative activity
of the mutant BMI1 [35], as the overexpression of the
ΔRF mutant of BMI1 induces p16INK4a expression and
premature senescence, whereas the expression of the wild
type BMI1 suppresses p16INK4a expression and bypasses
senescence in HDFs [35]. Alkema et al. also showed that
in addition to the RING finger domain, a centrally located
HTH domain of Bmi1 was also required for B- and T- cell
lymphomagenesis by Bmi1 and c-myc [49]. Interestingly,
the PS region of Bmi1 was not required to induce B- and
T- cell lymphomas in the mouse model [49]. Thus, at
present, it is not clear what role the PS domain of BMI1
plays in oncogenesis.
In the present study, we report that deletion of the PS
domain of BMI1 increases its half life and that the mutant
protein becomes very stable. Although naturally occur-
ring deletions in the PS region of BMI1 have not been
reported, our studies form the basis of detailed analysis of
posttranslational regulation of BMI1 and biochemical
analysis of its degradation pathways. With respect to bio-
c h e m i c a l  a n a l y s i s  o f  B M I 1  p r o t e o l y s i s ,  w e  n o t i c e d  t h e
Figure 5 MCF10A cells overexpressing the ΔPS mutant of BMI1 (MCF10A-BMI1ΔPS) exhibit an invasive phenotype in 3-D Matrigel culture. 
MCF10A-B0, MCF10A-BMI1WT and MCF10A-BMI1ΔPS cells were cultured in chamber slides in 2% Matrigel for 12 days and studied for Matrigel phe-
notype. Top panel shows the phase contrast images of the acini at day 12. At day 12, the cultures were fixed and immunostained using antibodies 
specific for E-cadherin (middle panel) and anti-α6 integrin (bottom panel). The nuclei were stained with Topro-3. After staining, acini were photo-
graphed (40X) using a Nikon Eclipse 80i confocal microscope.Yadav et al. Molecular Cancer 2010, 9:158
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presence of a degron motif DSG(X)2+nS, in the PS domain
of BMI1. The degron motif is a recognition site for the
βTRCP (β-transducin repeat containing protein), which
is a member of the F-box protein family and constitutes
one of the subunit of the ubiquitin ligase complex known
as SCF (SKP-Cullin-F-Box) [50]. The SCF complex is
involved in proteosome-mediated degradation of several
proteins known to be involved in cell cycle and oncogene-
sis such as CDC25A [51-53], Gli [54,55] Mcl-1 [56], and
PDCD4 [57]. It is tempting to speculate that a βTRCP-
based SCF complex posttranslationally regulates the sta-
bility of BMI1. Identification and detailed characteriza-
tion of such an SCF complex and its constituents remain
to be undertaken.
We reasoned that if the deletion of the PS region makes
BMI1 more stable, overexpression of the ΔPS mutant of
BMI1 may augment known biological activities of the
wild type protein and/or exhibit additional biological
activities. The best known biological activity of BMI1 is
regulation of proliferation, which it upregulates via
p16INK4a-dependent and -independent pathways. The
p16INK4a-independent pathway includes AKT and its
targets, and possibly other growth regulatory genes.
Indeed, our results indicate that deletion of the PS
domain of BMI1 results in augmentation of pro-prolifera-
tive activity of BMI1 via both p16INK4a-dependent and -
independent pathways in different cell types. Specifically,
overexpression of the ΔPS mutant in HMECs results in
upregulation of AKT and its targets such as cyclin D1,
and increased proliferation. On the other hand in pri-
mary HDFs, which express p16INK4a, overexpression of
the ΔPS mutant results in significant downregulation of
p16INK4a accompanied by increase in proliferation and
decrease in senescence.
Apart from the increase in proliferation in both epithe-
lial cells and fibroblasts, overexpression of the ΔPS
mutant also results in induction of an EMT phenotype,
which is often accompanied by downregulation of E-cad-
Figure 6 The ΔPS mutant of BMI1 promotes proliferation and bypasses senescence more efficiently than the wild type BMI1 in HDFs. (A). 
WI-38 cells expressing wild type BMI1 or ΔPS mutant of BMI1, and control WI-38-B0 cells were plated at 1 × 104 cells/well in multi well plates, and 
harvested and counted after indicated number of days. Proliferation curves were generated by plotting the number of cells against the number of 
days. (B). Mid passage control B0, and wild type BMI1- and ΔPS mutant-expressing cells were generated and serially passaged in culture to determine 
the effect of the mutant BMI1 on the long term replicative life span of WI-38 cells. After selection, at each passage 105 cells were passaged in a T25 and 
cultures were grown until 70-80% confluence. At each passage, cell numbers were counted and the proliferation curve was generated by plotting 
cumulative cell number vs days. (C). WI-38-derived cells were analyzed for the expression of p16INK4a, BMI1 (wild type and mutant), and α-tubulin 
(loading control) by western blot analysis as described in the Materials and Methods section. (D). The number of senescent cells in WI-38-B0, WI-38-
BMI1 WT and WI-38-BMI1 ΔPS culture at passage 3 (after selection) was determined using SA-β-gal staining as described in the Materials and Methods 
section. After staining, the cells were photographed (10X) under phase contrast using a light microscope. The number of senescent cells and total 
number of cells in each culture were counted in multiple fields to determine the percentage of senescent cells.Yadav et al. Molecular Cancer 2010, 9:158
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herin and upregulation of fibroblastic markers such as
fibronectin and vimentin. The EMT phenotype is
thought to be important not only for development of an
organism but also for certain pathological conditions
such as cancer and organ fibrosis [58]. PcG proteins, in
particular EZH2 has been shown to downregulate E-cad-
herin in breast and prostate cancer cells [59,60]. In addi-
tion, a recent report suggests that BMI1 can
downregulate E-cadherin expression and induce EMT via
d o w n r e g u l a t i o n  o f  P T E N  i n  n a s o p h a r y n g e a l  e p i t h e l i a l
cells (NEPC) [61]. However, our unpublished data sug-
gests that in HMECs, overexpression of the wild type
BMI1 is not sufficient to downregulate PTEN. It is possi-
ble that unidentified potential pro-oncogenic lesions in
immortalized NEPC and nasopharengeal carcinoma
cooperate with the wild type BMI1 to downregulate
PTEN expression and induce EMT. A different recent
report suggests that BMI1 interacts with nuclear PTEN
[62]. Interaction of BMI1 with PTEN may also inhibit its
function, and this interaction in part could induce an
EMT phenotype. Stable BMI1 in the form of the ΔPS
mutant may also upregulate EZH2, which in turn could
directly downregulate the CDH1 promoter and induce
EMT. These hypotheses remain to be examined. In any
case, it appears that by increasing BMI1 stability via dele-
tion of its negative regulatory sequences, one can poten-
tially induce EMT; although the mechanism of this
induction is not clear at this point.
Although the exact role of the PS domain of BMI1 in
the pathobiology of cancer remains to be explored, our
studies imply that under certain pathological conditions,
BMI1 may be more stable due to deregulation of its deg-
radation machinery, which is likely to be regulated by the
sequences present in the PS region of BMI1. So far there
is no report of somatic oncogenic mutations or deletions
occurring in the PS region of BMI1; however such a pos-
sibility cannot be ruled out. In summary, our data impli-
cates the PS domain of BMI1 in its negative regulation,
possibly via posttranslational mechanisms. Based on our
new and published data, we propose that the RING finger
domain of BMI1 can be classified as a catalytic domain,
while the PS domain of BMI1 can be termed as a regula-
tory domain. In view of the well established roles of BMI1
in oncogenesis and stem cell maintenance, our studies
have important implications for the pathobiology of can-
cer and the development of novel treatment strategies for
cancer patients.
BMI1 and its target p16INK4a are also important regu-
lators of in vivo aging. Recently it was shown that Bmi1-/-
mice present several growth defects, progeroid pheno-
type, such as hair loss, lens cataracts and reduced loco-
motor activity, and a high lethality rate exceeding 75%
[63]. Furthermore, the levels of p16INK4a , which is a well
established target of BMI1, but not other CDK inhibitors
increase with aging in vivo, and inhibition of p16INK4a
can ameliorate the physiological impact of aging on stem
cells and improve injury repair in aged tissues [64-68]. As
the deletion of the PS domain of BMI1 results in a stable
and constitutively active BMI1, and leads to a robust
downregulation of p16INK4a, we speculate that the PS
region of BMI1 could also be targeted for the develop-
ment of treatment strategies for age-related pathologies.
Methods
Cells, cell culture methods, and senescence and 
proliferation assays
The MCF10A cell line was obtained from ATCC (Manas-
sas, VA, USA), and cultured as described previously [69].
WI-38 and MRC5 strains of HDFs were obtained from
National Institute on Aging (NIA), Aging Cell Repository,
Coriell Institute for Medical Research, Camden, NJ.
HDFs were passaged in culture in DMEM containing 10%
FCS, 2 mM L-glutamine at 37°C under 10% CO2 and 90%
atmosphere as described [35,46,47,70]. The induction or
b ypas s  o f  se n e s c e n c e  i n  HD F s  e x p r e s s i n g  wi l d  t ype  o r
mutant BMI1 proteins was determined using histochemi-
cal staining for senescence-associated beta galactosidase
(SA-β-gal) marker as described [35,46,47,70]. Similarly,
short and long term proliferation assays were done as
described [35,46,47,70].
Retrovirus production, infection and generation of cells 
expressing wild type or mutant BMI1 proteins
The cDNA of mutant BMI1 protein lacking the PS
domain was generated by PCR and cloned into pBabe-
puro retroviral vector to generate pBabe-BMI1ΔPS. The
pBabe-BMI1 WT (wild type), pBabe-BMI1 ΔRF (RING
finger deleted) and pBabe-BMI1ΔHT (HTH domain
deleted) have been described previously [34,35] (Fig. 1A).
Retroviruses expressing wild type or mutant BMI1 pro-
teins were produced by transiently transfecting retroviral
vectors together with a packaging plasmid pIK into a
packaging cell line tsa54 as described [70]. After 24 hrs of
transfection, retrovirus-containing supernatant was col-
lected, filtered, and directly used to infect recipient cells
or was stored at -80°C as described [70]. After three
sequential infections, recipient cells were passaged in
medium containing puromycin (0.5-1 μg/ml) as
described [35,46,47,70]. The pool populations of drug-
selected cells were further passaged in culture and ana-
lyzed as necessary.
Antibodies and western blot analyses, and protein half life 
determination
Most of the antibodies were obtained from commercial
sources. These included; anti-BMI1 mAb (monoclonal
antibody) 1H6B10G7 from Invitrogen Corporation
(Camarillo, CA), anti-E-cadherin mAb and anti-vimentinYadav et al. Molecular Cancer 2010, 9:158
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mAb from BD Biosciences (San Jose, CA), anti-α6 integ-
rin mAb from Chemicon Corporation (now Millipore,
Billerica, MA), and mAb against β-actin from Sigma-
Aldrich (St. Louis, MO). Additionally, pAbs (polyconal
antibodies) against CDK4, phospho-AKT 1/2/3 (Ser-
473), and AKT-1/2/3, and mAbs against α-tubulin, E-cad-
herin, fibronectin, cyclin D1 and p16INK4a were
obtained from Santa Cruz Biotechnology (Santa Cruz,
CA). Antibodies against Phospho-GSK3β (Ser9) and total
GSK3β were obtained from Cell Signaling Technologies
(Danvers, MA).
Western blot analyses of total cell extracts from control
and wild type or mutant BMI1- expressing cells using var-
ious antibodies were performed as described [47]. The
half life of wild type and mutant BMI1 protein was deter-
mined using cyclohexamide (CHX) treatment of
MCF10A cells expressing BMI1 proteins as described
[47]. Briefly, sub confluent MCF10A cells expressing wild
type or mutant BMI1 proteins were treated with 100 μg/
mL CHX for various time points (0-240 min) to stop the
synthesis of new proteins. After the CHX-treatment, cell
lysates were prepared and analyzed for the expression of
BMI1 and α-tubulin. The normalized % residual BMI1
was plotted against the different time points to determine
the rate of proteolysis and the half-life of BMI1. For the
analysis of H2A K119Ub, total histones were prepared
using acid extraction method as described [71], and west-
ern blot analysis was carried out using a pAb against H2A
K119Ub (Millipore Inc., Billerica, MA).
Soft agar, invasion, migration and wound healing assays
Anchorage-independent growth assay using soft agar,
and invasion and migration assays were performed as
described [24,69]. Briefly, for invasion assays, 2.5 × 104
cells in 0.2 ml medium were added to the top chambers of
Matrigel-coated or control wells (BD Biosciences, San
Jose, CA), with D-medium containing EGF in the bottom
chamber. After 24 hr at 37°C, the cells on the top side
were removed by scraping, and the invaded cells were
fixed in methanol at -20°C and visualized using the Diff-
Quik stain (Dade Behring, Deerfield, IL). Live images
were taken under 10X magnification for counting of cells
that invaded through the Matrigel. The experiments were
done in triplicates and data were analyzed using the Stu-
dent's t test, for which P < 0.05 was considered signifi-
cant. For the wound healing assay, the MCF10A-derived
c e l l s  w e r e  g r o w n  t o  9 0 %  c o n f l u e n c e  i n  g r o w t h  f a c t o r
deprived D3 medium [24,69]. A wound was made in the
middle of culture dish containing near-confluent cells
a n d  t h e  c e l l s  w e r e  s t i m u l a t e d  w i t h  E G F  c o n t a i n i n g  D
medium. Cells were photographed at 0 hr, before adding
D medium and at 5 and 12 hr, after stimulating with D
medium. Cells were photographed using a light micro-
scope (4X).
Immunofluorescence and Matrigel assays
Immunofluorescence (IF) and Matrigel assays were per-
formed as described [24,69]. Briefly, cells were plated in
chamber slides. Cells were fixed in 4% formaldehyde, per-
meabilized with 0.5% Triton X-100 for 5 min, and immu-
nostained with anti-E-cadherin, anti-fibronectin, and
anti-vimentin antibodies followed by staining with Alexa
Fluor 488- and Alexa Fluor 594-conjugated secondary
antibodies (Molecular Probes Inc. Eugene, OR) as
required. The slides were mounted with Vectashield
mounting medium containing 4',6-diamidino-2-phe-
nylindole (DAPI) (Vector Laboratories). After staining,
the cells were photographed (40X) using a Nikon Eclipse
80i confocal microscope. To perform Matrigel assays,
cells were plated in 2% Matrigel in a chamber slide on top
of a polymerized layer of 100% Matrigel. The cultures
were fed every 3 days. Phase-contrast images were
obtained under 10X magnification. For immunofluores-
cence analyses, the cultures were fixed in 4% paraformal-
dehyde on day 12, permeabilized with 0.5% Triton X-100
for 5 min, and stained with anti-E-cadherin or anti-α6
integrin primary antibodies followed by Alexa Fluor 488-
conjugated secondary antibodies (Molecular Probes).
Nuclei were stained with Topro-3 and slides were
mounted with Vectashield mounting medium (Vector
Laboratories). Images were acquired with a Nikon Eclipse
80i confocal microscope.
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